Drug Profile
Recombinant human neuregulin-1 beta - Zensun (Shanghai) Sci & Tech
Alternative Names: Neucardin; Recombinant Human Neuregulin-1β; rhNRG-1; rhNRG-1 - Zensun; rhNRG-1-betaLatest Information Update: 20 Jul 2023
Price :
$50
*
At a glance
- Originator Zensun (Shanghai) Sci & Tech
- Class Anti-ischaemics; Antineoplastics; Glycoproteins; Heart failure therapies; Immunotherapies; Neuregulins; Peptide fragments; Vascular disorder therapies
- Mechanism of Action Neuregulin-1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Chronic heart failure
- Phase II Heart failure
- Preclinical Neurilemmoma
- No development reported Diastolic heart failure; Myocardial infarction; Stroke
Most Recent Events
- 13 Apr 2023 Zensun Sci & Tech initiates a phase III trial in Chronic heart failure in China (IV) (NCT05949801)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Myocardial-infarction in China
- 28 Jan 2023 No recent reports of development identified for preclinical development in Stroke in China